|
|
|
|
|
| Chevalme,Yanna-Marina; Montravers,Françoise; Vuillez,Jean-Philippe; Zanca,Michel; Fallais,Charles; Oustrin,Jean; Talbot,Jean-Noël. |
| Positron emission tomography (PET) and its recent update PET/CT are very effective diagnostic tools for non-invasive imaging of metabolic or functional disorders in target tissues. The clinical usefulness of fluorodeoxyglucose-(18F) (FDG) has been now widely accepted. Recently, the clinical usefulness of fluoroDOPA-(18F) or FDOPA, an aminoacid labelled with the same positron emitter fluorine-18, has been evaluated and recognised in France and subsequently in several EU countries. FDOPA is diagnostic PET agent, which has been used for decades in imaging the loss of dopaminergic neurons in Parkinson's disease, and more recently to detect, stage and restage neuroendocrine tumours and to search for recurrence of viable glioma tissue. The present article... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Registration of radiopharmaceuticals; PET; FDOPA; Parkinson's disease; Cancer. |
| Ano: 2007 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132007000600009 |
| |
|
|
| Talbot,Jean-Nöel; Chevalme,Yanna-Marina. |
| This short review is dedicated to the current status of the assessment of a new PET radiopharmaceutical, fluoromethylcholine-(18F) or FCH, which is taken-up by prostate cancer tissue, in contrary to fluorodeoxyglucose-(18F) or FDG. It seems that FCH could become "the FDG of prostate cancer", with the same type of achievements (detection of distant metastases and of occult recurrences, restaging prior to invasive treatments), and the same drawbacks (false negative results in case of small lesions, in particular lymph nodes metastases, and false positive results in case of infection/inflammation, in particular prostatitis). Current evidence is summarised and discussed for each of the potential settings of FCH PET/CT imaging in prostate cancer. The... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Fluoromethylcholine-(18F); PET/CT; Prostate cancer; Evaluation of radiopharmaceuticals. |
| Ano: 2008 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132008000700012 |
| |
|
|
|
